The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
Authors:
- Karmele ValenciaKVKarmele Valencia
- Oihane EriceOEOihane Erice
- Kaja KostyrkoKKKaja Kostyrko
- Simone HausmannSHSimone Hausmann
- Elizabeth GuruceagaEGElizabeth Guruceaga
- Natasha M. FloresNFNatasha M. Flores
- Leanne C. SaylesLSLeanne C. Sayles
- Alex G. LeeAlex G. Lee
- Rita FragosoRFRita Fragoso
- Tian-Qiang SunTSTian-Qiang Sun
- Adrian VallejoAVAdrian Vallejo
Open Access
- 9 March 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 130 (4) , 1879-1895
Abstract
Few therapies are currently available for patients with KRAS-driven cancers, highlighting the need to identify new molecular targets that modulate central downstream effector pathways. Here we found that the microRNA (miRNA) cluster including miR181ab1 is a key modulator of KRAS-driven oncogenesis. Ablation of Mir181ab1 in genetically engineered mouse models of Kras-driven lung and pancreatic cancer was deleterious to tumor initiation and progression. Expression of both resident miRNAs in the Mir181ab1 cluster, miR181a1 and miR181b1, was necessary to rescue the Mir181ab1-loss phenotype, underscoring their nonredundant role. In human cancer cells, depletion of miR181ab1 impaired proliferation and 3D growth, whereas overexpression provided a proliferative advantage. Lastly, we unveiled miR181ab1-regulated genes responsible for this phenotype. These studies identified what we believe to be a previously unknown role for miR181ab1 as a potential therapeutic target in 2 highly aggressive and difficult to treat KRAS-mutated cancers.Keywords
Funding Information
- European Commission (618312 KRASmiR FP7-PEOPLE-2013-CIG)
- Spanish Ministry of Economy and Competitiveness (SAF2013-46423-R)
- Worldwide Cancer Research (16-0224)
- RED TEMATICA DE INVESTIGACION COOPERATIVA EN RED (RD12/0036/0040)
- PHS Grant (4R01CA129562)
- National Institutes of Health (R00CA197816,P50CA070907,P30CA016672)
- National Institutes of Health (1R01AI073724,OD00643501)
- Spanish Ministry of Economy and Competitiveness (FJCI-2017-34233))
- Swiss National Science Foundation (P300PB-174377)
- European Commission (618312 KRASmiR FP7-PEOPLE-2013-CIG)
This publication has 83 references indexed in Scilit:
- The MicroRNA miR-181 Is a Critical Cellular Metabolic Rheostat Essential for NKT Cell Ontogenesis and Lymphocyte Development and HomeostasisImmunity, 2013
- Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21Cancer Cell, 2010
- Identification of microRNA‐181 by genome‐wide screening as a critical player in EpCAM–positive hepatic cancer stem cells†Hepatology, 2009
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- MicroRNA-Mediated Control of Cell Fate in Megakaryocyte-Erythrocyte ProgenitorsDevelopmental Cell, 2008
- Transactivation of miR-34a by p53 Broadly Influences Gene Expression and Promotes ApoptosisMolecular Cell, 2007
- A Mammalian microRNA Expression Atlas Based on Small RNA Library SequencingCell, 2007
- Expression profiling identifies microRNA signature in pancreatic cancerInternational Journal of Cancer, 2006
- c-Myc-regulated microRNAs modulate E2F1 expressionNature, 2005